What are the key drivers behind REGN's strong earnings report?

The key drivers behind Regeneron's (REGN) strong earnings report are as follows:

1. **Strong Sales of Key Treatments**: Regeneron's eye care therapy Eylea HD, cancer drug Libtayo, and immunology medicine Dupixent recorded substantial sales increases, contributing to the revenue growth.
2. **Collaboration and Product Launches**: The collaboration with Sanofi on Dupixent yielded a 29.7% increase in collaboration revenue versus Q2 2024, with Regeneron's share of Dupixent profits rising 30% to $1.28 billion. This highlights the success of strategic partnerships in driving revenue growth.
3. **Pipeline Progress**: Regeneron's ongoing pipeline progress and potential new indications for existing products, such as Dupixent, suggest a strong future growth potential.
4. **Strategic Investments**: The company's strategic investments and product launches across key segments have fueled growth and contributed to its financial performance.

These factors, among others, have collectively driven Regeneron's strong earnings performance.